Established in 2015, Centus Biotherapeutics represents a collaboration between AstraZeneca, a prominent global pharmaceutical company, and Fujifilm Kyowa Kirin Biologics (FKB), a Japanese biopharmaceutical enterprise specializing in biosimilar development. By combining top-tier biologics knowledge, worldwide commercial infrastructure, and extensive biosimilar development experience, Centus Biotherapeutics is strategically positioned to earn the confidence of medical professionals and address the requirements of patients on a global scale. On the other hand, Ducentis is a pre-clinical stage organization with the objective of creating innovative treatments for inflammation and autoimmune disorders. The focal point of Ducentis is the CD200/CD200R axis, which delivers a deactivating signal to activated immune cells within both the innate and adaptive branches of the immune system. Potential therapeutic areas include transplant rejection, as well as autoimmune and inflammatory conditions impacting the lungs, liver, kidney, eye, bone, and cartilage.